XENETIC BIOSCIENCES, INC. Foreign Currency Transaction Gain (Loss), before Tax
XENETIC BIOSCIENCES, INC. (XBIO) reported Foreign Currency Transaction Gain (Loss), before Tax of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-31.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2017-03-31
- XENETIC BIOSCIENCES, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2015-12-31 was -$23.56K, a 107.62% decline year-over-year.
- XENETIC BIOSCIENCES, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2015-09-30 was -$1.71K, a 100.90% decline year-over-year.
- XENETIC BIOSCIENCES, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2015-06-30 was -$344.68K.
- XENETIC BIOSCIENCES, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. foreign currency transaction gain (loss), before tax for fiscal 2016 was $0.00.
- XENETIC BIOSCIENCES, INC. foreign currency transaction gain (loss), before tax for fiscal 2015 was -$369.95K, a 204.52% decline from fiscal 2014.
- XENETIC BIOSCIENCES, INC. foreign currency transaction gain (loss), before tax for fiscal 2014 was $353.95K, a 2265.20% increase from fiscal 2013.
- XENETIC BIOSCIENCES, INC. foreign currency transaction gain (loss), before tax for fiscal 2013 was $14.96K, a 64.50% decline from fiscal 2012.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-31 | ||||
| 2015-12-31 | -$23.56K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | -$25.27K derived: sum of 2 quarters · filed 2017-03-31 | -$369.95K derived: sum of 3 quarters · filed 2017-03-31 | -$369.95K 10-K · filed 2017-03-31 | |
| 2015-09-30 | -$1.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | -$346.39K derived: sum of 2 quarters · filed 2015-11-16 | -$346.39K 10-Q · filed 2015-11-16 | -$37.17K derived: sum of 4 quarters · filed 2016-03-30 | |
| 2015-06-30 | -$344.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | -$344.68K 10-Q · filed 2015-08-19 | -$35.46K derived: sum of 3 quarters · filed 2016-03-30 | $154.94K derived: sum of 4 quarters · filed 2016-03-30 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-20 | $309.21K derived: sum of 2 quarters · filed 2016-03-30 | $499.62K derived: sum of 3 quarters · filed 2016-03-30 | $347.84K derived: sum of 4 quarters · filed 2016-03-30 | |
| 2014-12-31 | $309.21K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $499.62K derived: sum of 2 quarters · filed 2016-03-30 | $347.84K derived: sum of 3 quarters · filed 2016-03-30 | $353.95K 10-K · filed 2016-03-30 | $0.00 10-K · filed 2015-04-15 |
| 2014-09-30 | $190.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $38.62K derived: sum of 2 quarters · filed 2015-11-16 | $44.74K 10-Q · filed 2015-11-16 | ||
| 2014-06-30 | -$151.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | -$145.66K 10-Q · filed 2015-08-19 | |||
| 2014-03-31 | $6.11K 10-Q · filed 2015-05-20 | ||||
| 2013-12-31 | $14.96K 10-K · filed 2015-07-20 | ||||
| 2013-03-31 | -$41.97K 10-Q · filed 2014-05-20 | ||||
| 2012-12-31 | $42.16K 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |